September 2026 FDA Recall Imaavy by J&j Innovative Medicine
D-0016-2027 - Presence of particulate matter.
This Class II drug recall was voluntarily initiated by J&j Innovative Medicine on September 23, 2026 for the product Imaavy. The FDA reported the reason for recall as presence of particulate matter.. The product was distributed in OH and the recall is currently ongoing.
Recall Number: D-0016-2027
Presence of particulate matter.
09-23-2026
10-14-2026
49 vials
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Ongoing
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
J&J INNOVATIVE MEDICINE
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
OH
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Batch or Lot Expiration Information
Lot# Lot JNYJ1208; Exp. 10/30/2027